New liver cancer treatment plan for high-risk early-stage patients
Part of Cancer, Digestive system clinical trials.
This trial studies a treatment approach (a combination given through the liver) for people with early liver cancer that can be surgically removed but has a high chance of coming back. It may help reduce the risk of recurrence after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your liver cancer is considered early-stage (BCLC A) and has a high risk of coming back.
- Your main liver tumor can be surgically removed (resectable).
- Your liver function is fairly preserved: Child-Pugh A or B (score 7).
- After surgery, you should have more than 30% of working residual liver left.
- You have NOT had any other anti–liver-cancer treatment before joining the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
This trial tests a combination of treatments for liver cancer that can be surgically removed. It adds immunotherapy drugs (Iparomlimab and Tuvonralimab, together called QL1706) and targeted therapy (Lenvatinib) to a procedure called TACE (chemoembolization) to see if this approach shrinks the tumor and lowers the chance of recurrence after surgery.
This trial tests whether giving chemotherapy, immunotherapy, and targeted drugs before surgery helps prevent liver cancer from coming back in patients with high-risk tumors. You would receive treatment to shrink the tumor before your scheduled surgery.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver or into major blood vessels. It tests combining a procedure called TACE with immunotherapy (PD-1/PD-L1 inhibitors) and targeted drugs to see how well they work together.
This trial tests a combination of three treatments—two immunotherapy/anti-cancer drugs (bevacizumab and atezolizumab) plus a catheter-based liver treatment (TACE-HAIC)—for people with unresectable hepatocellular carcinoma (liver cancer that cannot be surgically removed). The goal is to slow or shrink the cancer.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.